Procter & Gamble Health Ltd on Monday (November 4) reported a 25.5% year-on-year (YoY) surge in net profit at ₹82.3 crore for the second quarter that ended September 30, 2024. In the corresponding quarter of the previous fiscal, Procter & Gamble Health posted a net profit of ₹65.6 crore.
Revenue from operations increased 2.8% to ₹313.4 crore against ₹304.9 crore in the year-ago period. At the operating level, EBITDA climbed 28.7% to ₹114.1 crore in the second quarter of this fiscal over ₹88.7 crore Q2 of FY24.
Also Read: Gland Pharma Q2 Results | Net profit falls 16% to ₹164 crore, R&D expenses at ₹49 crore
The EBITDA margin stood at 36.4% in the reporting quarter compared to 29.1% year-on-year. EBITDA is earnings before interest, tax, depreciation, and amortisation.
P&G Health reported a 3% YoY increase in sales for Q2 FY25, reaching ₹310 crore. The company also achieved an 8% rise in operational profit after tax (PAT) compared to the same period last year, excluding the effects of a one-time impact in the previous base period.
Milind Thatte, Managing Director, P&G Health India, said, “Our first quarter results represent a sequential improvement. Our strategy centred on a focused portfolio of quality, trusted, and highly recommended brands where performance drives brand choice; superiority (across product, package, brand communication, retail execution, and value), constructive disruption and an agile accountable organisation.”
Also Read: Amara Raja Energy Q2 Results | Net profit, revenue rise; declares dividend of ₹5.30/share
The results came after the close of the market hours. Shares of Procter & Gamble Health Ltd ended at ₹5,295.45, up by ₹99.05, or 1.91%, on the BSE.
(Edited by : Shoma Bhattacharjee)